Analyst Ratings for Spectrum Pharmaceuticals (SPPI)
SPPI Rating Summary
SPPI Price Target Summary
- Highest: $20.00 (Roth Capital)
- Lowest: $5.50 (WallachBeth Capital)
- Average: $15.25
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$15.25 (+87.3%)
Avg. $ Target:
$15.25 (+87.3%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/2/2013 | JMP Securities | New Coverage | Market Perform (N/A) |
N/A (N/A) |
7.29 | 8.14 | 11.66% | Details |
| 3/13/2013 | WallachBeth Capital | Downgrade | Sell (Buy) |
5.50 (N/A) |
12.43 | 8.14 | -34.51% | Details |
| 1/15/2013 | Credit Suisse | New Coverage | Neutral (N/A) |
15.00 (N/A) |
12.67 | 8.14 | -35.75% | Details |
| 11/27/2012 | Dawson James | New Coverage | Market Outperform (N/A) |
15.00 (N/A) |
11.28 | 8.14 | -27.84% | Details |
| 1/26/2012 | Roth Capital | Upgrade | Buy (N/A) |
20.00 (N/A) |
14.99 | 8.14 | -45.7% | Details |
| 9/30/2011 | Auriga » Updated 5/17/2012 |
New Coverage | Buy (N/A) |
18.00 (N/A) |
7.53 | 8.14 | 8.1% | Details |
| 3/25/2011 | RBC Capital | New Coverage | Outperform (N/A) |
N/A (N/A) |
8.33 | 8.14 | -2.28% | Details |
| 3/11/2011 | Capstone Investments | Upgrade | Buy (N/A) |
N/A (N/A) |
7.58 | 8.14 | 7.39% | Details |
